• May 25, 2026
Linkedin-in X-twitter Youtube Tiktok Instagram

Drug Pricing & Market Access: What Pharma Leaders Need to Know

Drug Pricing & Market Access: What Pharma Leaders Need to Know

Drug pricing is the most politically charged—and commercially consequential—topic in pharma right now. Between IRA negotiation, PBM reform, 340B disputes, and Most Favored Nation pressure, the rules are changing faster than most commercial teams can track. This hub collects M2M’s practitioner-depth coverage in one place: no news summaries, no policy theater—just the implications for teams building and defending drug franchises.

IRA Drug Price Negotiation

The Inflation Reduction Act’s negotiation program is restructuring the economics of late-lifecycle brands. The first 10 negotiated drugs established the precedent. What happens to your pipeline if a similar-stage asset ends up in round three or four?

Most Favored Nation Pricing

MFN pricing—pegging US drug prices to international reference prices—has been on the policy agenda for years. The Trump administration has moved it from threat to executive order. The downstream implications for brand strategy and payer negotiations are real and largely underappreciated.

Pharmacy Benefit Managers (PBMs)

PBMs are the fulcrum of formulary access, and they’re under sustained regulatory pressure from both the FTC and Congress. For brand teams, PBM reform is both a risk (rebate restructuring) and an opportunity (more transparent contracting). Neither will materialize the way it’s being described in press releases.

340B Program

The 340B program has become a proxy war between large pharma manufacturers and covered entities—with hospitals, contract pharmacies, and patient advocates all claiming different high grounds. The legal and strategic landscape here shifts constantly. The M2M coverage below focuses on what the battles mean for commercial teams, not just who’s winning in court.

Biosimilar Pricing & Market Access

The Humira biosimilar wave was supposed to be a market access inflection point. What actually happened is more instructive: payer behavior, rebate walls, and PBM formulary tactics all shaped the outcome in ways that will replay for the next major LOE brand. Watch this space carefully if you have a biologic franchise.

Pharma Tariffs & Trade Policy

The intersection of trade policy and drug pricing is new territory for most pharma commercial teams. Tariff exposure on API and finished goods, combined with pricing pressure from the administration, creates a compounding headwind. The implications aren’t theoretical anymore.

Executive Strategies & Industry Response

How are pharma executives actually responding? The range spans from proactive negotiation deals to legal challenges to portfolio restructuring. The strategic logic behind each approach—and what it signals about where leadership thinks the pricing environment is heading—is worth paying attention to.